Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II trial of GP-1681 for the treatment of COVID-19 infection

Next Previous
Trial Profile

A Phase II trial of GP-1681 for the treatment of COVID-19 infection

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GP 1681 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors CytoAgents

Most Recent Events

  • 10 Mar 2021 According to a CytoAgents media release, this trial is slated to begin by mid-2021.
  • 13 Oct 2020 According to a CytoAgents media release, the trial is anticipated to begin after the phase I study results which are expected in 2021.
  • 13 May 2020 According to a CytoAgents media release, the company has received a Phase II SBIR grant of $1.6 million is non-dilutive funding from the National Institute of Allergy and Infectious Diseases of the NIH, under Award Number 1R44AI152726-01, which will be used for this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top